MUC1 and intrahepatic cholangiocarcinoma: For example, Ganguly et al. found that secretory MUC5AC promoted neoplastic progression by augmenting KLF4-mediated pancreatic cancer cell stemness [7]; Xu et al. indicated that MUC1 was overexpressed in NSCLC and silence of MUC1 alleviated paclitaxel resistance of NSCLC [8]; Gao et al. suggested that MUC12 enhanced RCC progression by regulating c-Jun/TGF-β signaling [9]; Tiemin et al. found that MUC13 facilitated progression of intrahepatic cholangiocarcinoma via EGFR/PI3K/AKT pathways [10].